Quest Diagnostics Incorporated $DGX Stock: Robeco Institutional Asset Management B.V. Raises Position

Key Points

• Robeco Institutional Asset Management increased its Quest Diagnostics position by 8.7% in the third quarter, bringing its holdings to 122,316 shares valued at approximately $31.2 million. Institutional investors collectively own 88.06% of DGX.
• Analysts maintain a generally favorable outlook, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $243.64; ratings include one Strong Buy, three Buys and six Holds.
• Quest Diagnostics exceeded quarterly expectations, reporting $3.00 in EPS and $3.10 billion in revenue, up 10% year over year. The company also pays a quarterly dividend of $0.86, while an investigation into unauthorized access to its Quanum LSM system presents potential operational and reputational risks.

Robeco Institutional Asset Management B.V. raised its holdings in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 8.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 122,316 shares of the medical research company's stock after purchasing an additional 9,770 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.11% of Quest Diagnostics worth $31,198,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Diversify Advisory Services LLC raised its stake in shares of Quest Diagnostics by 19.7% during the 3rd quarter. Diversify Advisory Services LLC now owns 4,724 shares of the medical research company's stock worth $1,101,000 after buying an additional 778 shares during the period. Prime Capital Investment Advisors LLC lifted its position in shares of Quest Diagnostics by 257.7% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 3,416 shares of the medical research company's stock valued at $796,000 after buying an additional 2,461 shares in the last quarter. Net Worth Advisory Group grew its stake in Quest Diagnostics by 47.5% in the 3rd quarter. Net Worth Advisory Group now owns 7,129 shares of the medical research company's stock valued at $1,662,000 after acquiring an additional 2,296 shares during the period. Focused Alpha LLC grew its stake in Quest Diagnostics by 50.6% in the 3rd quarter. Focused Alpha LLC now owns 4,509 shares of the medical research company's stock valued at $1,051,000 after acquiring an additional 1,515 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in Quest Diagnostics by 47.0% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 23,513 shares of the medical research company's stock valued at $5,480,000 after acquiring an additional 7,514 shares during the period. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on DGX shares. Argus set a $260.00 price target on shares of Quest Diagnostics in a report on Wednesday, July 29th. Truist Financial increased their price objective on shares of Quest Diagnostics from $250.00 to $260.00 and gave the company a "hold" rating in a report on Monday, September 21st. JPMorgan Chase & Co. lifted their target price on shares of Quest Diagnostics from $220.00 to $250.00 and gave the company a "neutral" rating in a research report on Tuesday, July 28th. UBS Group reissued a "neutral" rating and set a $250.00 target price on shares of Quest Diagnostics in a research note on Monday. Finally, Mizuho boosted their target price on shares of Quest Diagnostics from $235.00 to $260.00 and gave the stock an "outperform" rating in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $243.64.

Quest Diagnostics Stock Performance

NYSE DGX opened at $244.90 on Friday. The company has a market cap of $27.03 billion, a PE ratio of 22.46, a price-to-earnings-growth ratio of 2.16 and a beta of 0.54. The stock's 50 day simple moving average is $237.53 and its 200-day simple moving average is $216.64. Quest Diagnostics Incorporated has a 1-year low of $171.18 and a 1-year high of $248.84. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46.

Quest Diagnostics (NYSE:DGX - Get Free Report) last issued its quarterly earnings results on Thursday, October 22nd. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.87 by $0.13. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%. The firm had revenue of $3.10 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same period in the previous year, the company posted $2.60 earnings per share. The business's revenue was up 10.0% on a year-over-year basis. As a group, equities research analysts anticipate that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 21st. Shareholders of record on Tuesday, October 6th were issued a $0.86 dividend. The ex-dividend date was Tuesday, October 6th. This represents a $3.44 dividend on an annualized basis and a yield of 1.4%. Quest Diagnostics's dividend payout ratio (DPR) is presently 36.52%.

Insider Buying and Selling at Quest Diagnostics

In other Quest Diagnostics news, SVP Mark Delaney sold 1,600 shares of Quest Diagnostics stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total transaction of $376,288.00. Following the sale, the senior vice president owned 10,335 shares of the company's stock, valued at $2,430,585.30. The trade was a 13.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. Davis sold 10,000 shares of Quest Diagnostics stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $242.72, for a total transaction of $2,427,200.00. Following the sale, the chief executive officer directly owned 122,423 shares in the company, valued at approximately $29,714,510.56. This trade represents a 7.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 34,277 shares of company stock worth $8,316,493. Corporate insiders own 0.88% of the company's stock.

Trending Headlines about Quest Diagnostics

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Quarterly results exceeded expectations. Quest reported third-quarter revenue of $3.10 billion, up 10% year over year, while adjusted diluted EPS reached $3.00 versus the $2.87 analyst consensus. Reported diluted EPS was $2.78, up 28.7% from the prior year. Quest Diagnostics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Quest raised its 2026 outlook. The company now expects revenue of $12.065 billion to $12.105 billion, reported EPS of $10.21 to $10.31, and adjusted EPS of $11.25 to $11.35. Management cited strong testing demand, volume growth and margin gains. DGX Q3 Earnings and Guidance
• Positive Sentiment: Underlying demand trends were encouraging. Organic requisition volume rose 14.4% in the quarter, and consumer health revenue is expected to grow by more than 30% in 2026, supporting Quest’s longer-term growth strategy. Quest Diagnostics Long-Term Investor Takeaways
• Neutral Sentiment: The market response was mixed. Although the earnings and revenue beats were constructive, some coverage characterized the quarter as merely “good enough,” suggesting that elevated valuation and already-high expectations limited the upside reaction.
• Negative Sentiment: Quest is investigating unauthorized access to its Quanum LSM system. The cybersecurity incident introduces potential operational, remediation, legal and reputational risks, although the company’s ultimate impact assessment was not yet clear. Quest Diagnostics Quanum System Breach

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated NYSE: DGX is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.